Compare CIVB & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIVB | PRTC |
|---|---|---|
| Founded | 1884 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.4M | 464.3M |
| IPO Year | N/A | N/A |
| Metric | CIVB | PRTC |
|---|---|---|
| Price | $23.84 | $17.46 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $26.00 | N/A |
| AVG Volume (30 Days) | ★ 97.6K | 3.9K |
| Earning Date | 01-29-2026 | 08-28-2025 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | ★ 31.34 | N/A |
| EPS | ★ 2.64 | 0.20 |
| Revenue | ★ $169,173,000.00 | $6,391,000.00 |
| Revenue This Year | $15.24 | N/A |
| Revenue Next Year | $6.52 | N/A |
| P/E Ratio | $9.03 | ★ $8.37 |
| Revenue Growth | 13.47 | ★ 1265.60 |
| 52 Week Low | $17.47 | $13.30 |
| 52 Week High | $25.59 | $20.00 |
| Indicator | CIVB | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 45.00 |
| Support Level | $23.35 | $18.31 |
| Resistance Level | $25.40 | $18.98 |
| Average True Range (ATR) | 0.82 | 0.54 |
| MACD | -0.06 | -0.18 |
| Stochastic Oscillator | 43.50 | 5.75 |
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.